Evidence map›Paper›PMID 31222589›Full record

ArticleHead and neck pathology2020

SOX10 and GATA3 in Adenoid Cystic Carcinoma and Polymorphous Adenocarcinoma.

Brian D Adkins, Ariana Geromes, Lily Y Zhang, Rebecca Chernock, Katherine Kimmelshue, James Lewis, Kim Ely

Open access · bronzeAbstract read
In one paragraph

Article in Head and neck pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Clinical Significance of SOX10 Expression in Human Pathology.Current issues in molecular biology · 2023
    Review
  9. [Clinicopathological study in 28 cases of oral basaloid squamous cell carcinomas].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2022
    Article
  10. Review
  11. Polymorphous Adenocarcinoma.Surgical pathology clinics · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Brian D AdkinsDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, 1161 21st Avenue South, MCN CC3322, Nashville, TN, 37232-2561, USA.
Ariana GeromesDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, 1161 21st Avenue South, MCN CC3322, Nashville, TN, 37232-2561, USA.
Lily Y ZhangDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Rebecca ChernockDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Katherine KimmelshueDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, 1161 21st Avenue South, MCN CC3322, Nashville, TN, 37232-2561, USA.
James LewisDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, 1161 21st Avenue South, MCN CC3322, Nashville, TN, 37232-2561, USA.
Kim ElyDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, 1161 21st Avenue South, MCN CC3322, Nashville, TN, 37232-2561, USA. kim.ely@vumc.org.
Vanderbilt University Medical Center · USWashington University in St. Louis · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
NCI/NIH Cancer Center Support Grant 2P30 CA068485-14NCI NIH HHS P30 CA068485NIDDK NIH HHS U24 DK059637School of Medicine, Vanderbilt University 5U24DK059637-1
6 · The paper itself

Abstract

Differentiating between adenoid cystic carcinoma (AdCC) and polymorphous adenocarcinoma (PAC) can be difficult on small biopsies and cytologic specimens. As such, further characterization of their immunophenotype may aid in distinction. Previous studies have found AdCC to be SOX10+/GATA3 variable and PAC to be GATA3 negative. SOX10 expression in PAC has, as yet, not been established. We performed GATA3 and SOX10 immunohistochemistry on whole sections of 25 cases each of AdCC and PAC (including both classic PAC and the cribriform variant) to assess whether these markers are of diagnostic utility in distinguishing between these entities. SOX10 was found to be positive in 100% of PAC and AdCC whereas GATA 3 was immunoreactive in 45% of AdCCs and 20% of PAC. While this is the first series to compare SOX10 and GATA3 staining in these two tumor types, their frequent expression and similar staining patterns render them of limited value in discriminating between these neoplasms.

Indexed as

AdenocarcinomaBiomarkers, TumorCarcinoma, Adenoid CysticDiagnosis, DifferentialGATA3 Transcription FactorHumansSalivary Gland NeoplasmsSOXE Transcription FactorsBiomarkers, TumorGATA3 protein, humanGATA3 Transcription FactorSOX10 protein, humanSOXE Transcription FactorsAdenoid cystic carcinomaGATA3Polymorphous adenocarcinomaSalivary glandSOX10

Identifiers

PMID31222589
PMCPMC7235140
OpenAlexW2950165124

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.